# Tukysa (tucatinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tucatinib

> The FDA approved Tukysa (tucatinib), sponsored by PFIZER INC (PFE), on April 17, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tukysa (tucatinib) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | [Breast Neoplasms](https://sec-api.dev/indications/breast-neoplasms), [Colorectal Neoplasms](https://sec-api.dev/indications/colorectal-neoplasms), [HER2 Positive Breast Cancer](https://sec-api.dev/indications/her2-positive-breast-cancer) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 17, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213411 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200417, review_priority PRIORITY; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22

### January 19, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213411 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230119, review_priority PRIORITY; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22

### September 5, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: HER2 Positive Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05132582 (A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-05 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-09-29." https://clinicaltrials.gov/study/NCT05132582

### September 29, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: HER2 Positive Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05132582 (A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-05 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-09-29." https://clinicaltrials.gov/study/NCT05132582?tab=results

### October 7, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213411 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20261007, review_priority STANDARD; sponsor_name SEAGEN; product TUKYSA (TUCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213411%22

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colorectal Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." https://clinicaltrials.gov/study/NCT05253651

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colorectal Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05253651 (A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." https://clinicaltrials.gov/study/NCT05253651

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06157892 (A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-07-28 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." https://clinicaltrials.gov/study/NCT06157892

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Breast Neoplasms; Gastroesophageal Junction Adenocarcinoma; HER2 Low Breast Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06157892 (A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-07-28 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." https://clinicaltrials.gov/study/NCT06157892

## Same indication

- [VERZENIO (abemaciclib)](https://sec-api.dev/pdufa/abemaciclib) (LLY)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [RYBREVANT (amivantamab)](https://sec-api.dev/pdufa/amivantamab) (JNJ)
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant) (LLY)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [Lonsurf](https://sec-api.dev/pdufa/lonsurf) (BMY)
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib) (LLY)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Tisotumab vedotin](https://sec-api.dev/pdufa/tisotumab-vedotin) (PFE)
- [(z)-endoxifen](https://sec-api.dev/pdufa/z-endoxifen) (ATOS)

Calendar months: [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tucatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tukysa (tucatinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tucatinib

```bibtex
@misc{secapidev_pdufa_tucatinib_20261116,
  title        = {Tukysa (tucatinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tucatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tucatinib_20261116","title":"Tukysa (tucatinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tucatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
